Fig. 1.

Schematic of PRX302 activation. PRX302 contains a C-terminal inhibitory domain (green) that must be proteolytically removed for activation to occur. Prostate-specific antigen processing can occur in solution as well as after binding of PRX302 to glycosylphosphatidylinositol-anchored proteins (dark blue) on the cell surface. Activated, cell surface–bound aerolysin inserts into membranes and oligomerizes to form a stable heptameric pore (red). Pore formation leads to rapid lytic cell death.

PSA = prostate-specific antigen.